nicotine has been researched along with ketanserin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Andersson, KE; Forman, A; Funch-Jensen, P; Raundahl, U; Tøttrup, A | 1 |
| Markus, JK; Mylecharane, EJ; Phillips, CA; Shaw, J | 2 |
| Dusting, GJ; Li, DM | 1 |
| Agnati, LF; Andersson, K; Eneroth, P; Fuxe, K; Härfstrand, A | 1 |
| Lajtha, A; Lapin, EP; Maker, HS; Reilly, MA | 1 |
| Damaj, MI; Glennon, RA; Martin, BR | 1 |
| Björklund, M; Jäkälä, P; Koivisto, E; Puolivali, J; Riekkinen, P | 1 |
| Araki, H; Gomita, Y; Suemaru, K; Yasuda, K | 1 |
| Caldwell, DP; Levin, ED; Rezvani, AH | 1 |
| Hayslett, RL; Tizabi, Y | 1 |
| Farzad, A; Icenogle, L; Levin, E | 1 |
| Horton, K; Johnson, M; Levin, ED; Petro, A; Rezvani, AH; Rose, JE; Slade, S; Williams, P | 1 |
1 review(s) available for nicotine and ketanserin
| Article | Year |
|---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
21 other study(ies) available for nicotine and ketanserin
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of transmural field stimulation in isolated muscle strips from human esophagus.
Topics: Atropine; Carbachol; Electric Stimulation; Esophagus; Humans; In Vitro Techniques; Ketanserin; Muscle Contraction; Muscle, Smooth; Nicotine; Phentolamine; Prazosin; Propranolol; Stomach; Tetrodotoxin; Yohimbine | 1990 |
Evidence for a central component to the hypotensive action of ketanserin in the dog.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Dogs; Ganglionic Blockers; Hexamethonium Compounds; Ketanserin; Mecamylamine; Nicotine; Norepinephrine; Piperidines; Vasoconstriction | 1985 |
Hypotensive actions of ketanserin in dogs: involvement of a centrally mediated inhibition of sympathetic vascular tone.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Dogs; Female; Heart Rate; Hexamethonium; Hexamethonium Compounds; Ketanserin; Male; Mecamylamine; Nicotine; Piperidines; Sympathetic Nervous System; Vascular Resistance; Vasomotor System | 1985 |
Catecholamine release and potentiation of thromboxane A2 production by nicotine in the greyhound.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Blood Pressure; Catecholamines; Dioxanes; Dogs; Epinephrine; Female; Heart Rate; Idazoxan; Imidazoles; In Vitro Techniques; Ketanserin; Male; Nicotine; Phenoxybenzamine; Piperidines; Thromboxane A2; Vasoconstriction | 1986 |
Involvement of D1 dopamine receptors in the nicotine-induced neuro-endocrine effects and depletion of diencephalic catecholamine stores in the male rat.
Topics: Animals; Benzamides; Benzazepines; Corticosterone; Diencephalon; Dopamine Antagonists; Ketanserin; Male; Nicotine; Pituitary Hormones, Anterior; Raclopride; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Reference Values; Remoxipride; Salicylamides; Smoke; Testosterone | 1988 |
Chronic nicotine administration increases binding of [3H]domperidone in rat nucleus accumbens.
Topics: Animals; Binding Sites; Domperidone; Ketanserin; Male; Nicotine; Nucleus Accumbens; Rats; Rats, Inbred Strains; Receptors, Dopamine; Septal Nuclei | 1987 |
Involvement of the serotonergic system in the hypoactive and antinociceptive effects of nicotine in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Ketanserin; Locomotion; Male; Mice; Mice, Inbred ICR; Nicotine; Nociceptors; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Spiperone | 1994 |
Activation of acetylcholine receptors and 5-HT2 receptors have additive effects in the suppression of neocortical high-voltage spindles in aged rats.
Topics: Animals; Cerebral Cortex; Drug Interactions; Electrophysiology; Ketanserin; Male; Muscarinic Agonists; Nicotine; Nicotinic Agonists; Pilocarpine; Rats; Rats, Wistar; Receptors, Serotonin; Serotonin Receptor Agonists | 1997 |
Effect of nicotine cessation on the central serotonergic systems in mice: involvement of 5-HT(2) receptors.
Topics: Amphetamines; Analysis of Variance; Animals; Brain; Dopamine; Dose-Response Relationship, Drug; Head Movements; Injections, Intraventricular; Ketanserin; Male; Mice; Mice, Inbred BALB C; Nicotine; Receptors, Nicotinic; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Substance Withdrawal Syndrome | 2002 |
Nicotinic-serotonergic drug interactions and attentional performance in rats.
Topics: Animals; Attention; Dose-Response Relationship, Drug; Drug Interactions; Female; Ketanserin; Nicotine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2005 |
Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome.
Topics: Amphetamines; Animals; Behavior, Animal; Binding, Competitive; Cerebral Cortex; Corpus Striatum; Donepezil; Dose-Response Relationship, Drug; Frontal Lobe; Gene Expression; Haloperidol; Humans; Indans; Ketanserin; Male; Mesencephalon; Mice; Mice, Inbred ICR; Nicotine; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serotonin Antagonists; Tourette Syndrome | 2005 |
Ketanserin attenuates nicotine-induced working memory improvement in rats.
Topics: Animals; Drug Interactions; Female; Ketanserin; Maze Learning; Memory, Short-Term; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT2; Serotonin Antagonists | 2005 |
Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ketanserin; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Self Administration; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Tobacco Use Disorder | 2008 |